Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
11 déc. 2024 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”),...
Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering
22 nov. 2024 09h15 HE
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted...
Nearly 350 Patients Participate in the Foundation for Sarcoidosis Research Externally Led Patient-Focused Drug Development Meeting with the FDA
31 oct. 2024 15h28 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research (FSR) hosts Externally Led Patient-Focused Drug Development (EL-PFDD) meeting for Sarcoidosis
Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial
26 août 2024 14h36 HE
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
13 août 2024 08h00 HE
|
Autonomix Medical, Inc.
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the source Positive 7-day topline results from first...
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
21 mars 2024 17h00 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
PatchMD Announce New Content Resource Center on Menopause to Offer Women Advice on Symptoms, Signs, and The Latest Treatments
29 nov. 2023 09h00 HE
|
PatchMD
Las Vegas, Nevada, Nov. 29, 2023 (GLOBE NEWSWIRE) -- PatchMD, innovative vitamin patches designed to optimize an individual’s daily nutrient intake, is proud to announce the launch of the new...
Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
15 nov. 2023 11h22 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK...
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q3 2023 Results
09 nov. 2023 14h45 HE
|
Harvard Apparatus Regenerative Technology, Inc.
HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“HRGN” or the “Company”), a clinical-stage biotechnology company developing the...
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
12 oct. 2023 08h45 HE
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and...